The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Anupam Rasayan India Ltd

Date:September30,2026 To, T o , T o , BSE Limited, National Stock Exchange of Bliss GVS Pharma Limited Phiroze Jeejeebhoy India Limited 102, Hyde Park, Sakivihar Road, Towers, ‘ExchangePlaza’,C-1, Block-G, Andheri (East), Mumbai- 400072, Dalal Street, Bandra Kurla Complex, Bandra India Mumbai-400001, India (East), Mumbai-400051, India DearSir/Madam, Subject: DisclosureunderRegulation29(1)oftheSecuritiesandExchangeBoardofIndia (SubstantialAcquisitionofSharesandTakeovers)Regulations,2011(“Takeover Regulations”) Ref.: BlissGVSPharmaLimited(BSEScripCode:506197,NSESymbol:BLISSGVS) Please find enclosed disclosure under Regulation 29(1) of the Takeover Regulations (with PAN details) in relation to the acquisition of equity shares of Bliss GVS Pharma Limited by Anupam RasayanIndiaLimitedandMatesVisaConsultancyPrivateLimited. We request you to kindly note the same and take into your records. Thankingyou, Yoursfaithfully, ForandonbehalfofAnupamRasayanIndiaLimited(Acquirer) Digitally signed by Anand Anand Sureshbhai Desai Sureshbhai Desai Date: 2026.09.30 17:47:37 +05'30' AnandSureshbhaiDesai ManagingDirector DIN:00038442 ForandonbehalfofMatesVisaConsultancyPrivateLimited(PAC) KALPESH Digitally signed by KALPESH HEMANTBHAI HEMANTBHAI PANCHAL Date: 2026.09.30 16:33:11 PANCHAL +05'30' KalpeshHemantbhaiPanchal Director DIN:10058215 Encl:Asabove Disclosure under Regulation 29(1) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 Part-A- Details of the Acquisition NameoftheTargetCompany(“TC”) Bliss GVS Pharma Limited Name(s) of the acquirer and Persons Acting in Concert Anupam Rasayan India Limited (“Acquirer”) (PAC) with the acquirer and Mates Visa Consultancy Private Limited (“PAC”) Whether the acquirer belongs to Promoter/Promoter group Yes. Please refer to the Notes. Name(s) of the Stock Exchange(s) where the shares of TC are BSE Limited and the National Stock Exchange of Listed India Limited Details of the acquisition as follows Number % w.r.t. total % w.r.t. share/voting total capital diluted wherever share/voti applicable(*) ng capital of the TC (**) Before the acquisition under consideration, holding of acquirer along with PACs of: a) Shares carrying voting rights 22,51,669^ 2.12%^ 2.07%^ b) Shares in the nature of encumbrance (pledge/ lien/ 0 0% 0% non-disposal undertaking/ others) c) Voting rights (“VR”) otherwise than by equity 0 0% 0% shares d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive 0 0% 0% shares carrying voting rights in the TC (specify holding in each category) e) Total (a+b+c+d) 22,51,669^ 2.12%^ 2.07%^ Details of acquisition a) Shares carrying voting rights acquired 5,09,84,595# 47.95%# 46.77%# b) VRs acquired otherwise than by equity shares 0 0% 0% c) Warrants/convertible securities/any other 0 0% 0% instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition 0 0% 0% d) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others) 5,09,84,595# 47.95%# 46.77 e) Total (a+b+c+d) After the acquisition, holding of acquirer along with PACs a) Shares carrying voting rights 5,32,36,264^# 50.07%^# 48.84%^# b) VRs otherwise than by equity shares 0 0% 0% c) Warrants/convertible securities/any other 0 0% 0% instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition d) Shares in the nature of encumbrance (pledge/ lien/ 0 0% 0% non-disposal undertaking/ others) e) Total (a+b+c+d) 5,32,36,264^# 50.07%^# 48.84%^# Mode of acquisition (e.g. open market / public issue / rights Acquisition pursuant to the Share Purchase issue / preferential allotment / inter-se Agreement read with the Deed of Adherence (as transfer/encumbrance, etc.) defined in the letter of offer dated 18 July 2026). Please refer to the Notes. Salient features of the securities acquired including time till Equity shares carrying voting rights. redemption, ratio at which it can be converted into equity shares, etc. Date of acquisition of / date of receipt of intimation of 28 September 2026 allotment of shares / VR/ warrants/convertible Please refer to the Notes for further details. securities/any other instrument that entitles the acquirer to receive shares in the TC. Equity share capital / total voting capital of the TC before 10,60,56,222 equity shares of the TC (as per the the said acquisition shareholding pattern for the quarter ended 30 June 2026, as publicly disclosed by the TC on the websites of the stock exchanges). Subsequently, the TC disclosed increases to its total paid up equity share capital following allotments of equity shares to eligible employees who exercised their stock options under the Bliss GVS Pharma Limited–Employee Stock Option Plan 2019, as follows: (i) on 7 July 2026, to 10,62,43,972 equity shares; (ii) on 11 August 2026, to 10,62,75,222 equity shares; and (iii) on 4 September 2026, to 10,63,30,472 equity shares. Accordingly, in compliance with Regulation 29(1) of the SEBI (SAST) Regulations, the total share capital of the TC as disclosed by the TC on 4 September 2026 (i.e., 10,63,30,472 equity shares) has been considered for the purposes of calculation for this acquisition. Equity share capital/ total voting capital of the TC after the 10,60,56,222 equity shares of the TC (as per the said acquisition shareholding pattern for the quarter ended 30 June 2026, as publicly disclosed by the TC on the websites of the stock exchanges). Subsequently, the TC disclosed increases to its total paid up equity share capital following allotments of equity shares to eligible employees who exercised their stock options under the Bliss GVS Pharma Limited–Employee Stock Option Plan 2019, as follows: (i) on 7 July 2026, to 10,62,43,972 equity shares; (ii) on 11 August 2026, to 10,62,75,222 equity shares; and (iii) on 4 September 2026, to 10,63,30,472 equity shares. Accordingly, in compliance with Regulation 29(1) of the SEBI (SAST) Regulations, the total share capital of the TC as disclosed by the TC on 4 September 2026 (i.e., 10,63,30,472 equity shares) has been considered for the purposes of calculation for this acquisition. Total diluted share/voting capital of the TC after the said 10,86,91,222 equity shares of the TC (as per the acquisition shareholding pattern for the quarter ended 30 June 2026, as publicly disclosed by the TC on the websites of the stock exchanges) On 12 August 2026, the Nomination and Remuneration Committee of the TC granted 3,20,000 stock options under the Bliss GVS Pharma Limited– Employee Stock Options Plan 2019. Accordingly, in compliance with Regulation 29(1) of the SEBI (SAST) Regulations, the latest publicly available total diluted share capital of the TC as on 12 August 2026 (i.e., 10,90,11,222 equity shares) has been considered for the purposes of calculation for this acquisition ^The Acquirer acquired (i) 1669 equity shares of the TC, representing 0.00% of the paid-up equity share capital of the Target Company, pursuant to the completion of the Open Offer (as defined in the letter of offer dated 18 July 2026); and (ii) 22,50,000 equity shares of the TC, representing 2.12% of the paid-up equity share capital of the Target Company, pursuant to an on-market transaction. Collectively, the Acquirer holds 22,51,669 equity shares of the TC, representing 2.12% of the paid-up equity share capital of the Target Company. # The PAC has acquired 50,984,595 equity shares of the TC, representing 47.95% of the paid-up equity share capital of the TC, pursuant to the Share Purchase Agreement read with the Deed of Adherence (as defined in the letter of offer dated 18 July 2026). Part-B*** Name of the Target Company: Bliss GVS Pharma Limited Name(s) of the acquirer and Persons Acting Whether the acquirer belongs to PAN of the acquirer and/ or in Concert (PAC) with the acquire [Showing first 8,000 characters — download PDF for full document]